Method for predicting the risk of late-onset alzheimer's diseases
Assigneebiotx.ai GmbH
InventorsJörn Klinger, Marco Schmidt
Life of this patent
Estimating the term…
Abstract
A method for prognosis, risk assessment, risk stratification and/or diagnosis of a subject of developing late-onset Alzheimer's disease (LOAD), includes providing at least one sample isolated from the subject, and determining in the presence of ApoE4 and either rs1799931(G) or rs8192506(A), rs7653308(C), rs968529(C) and rs9658265(A). The presence or absence of these markers is indicative of a prognosis, a risk and/or a diagnosis of developing LOAD.
Claims15
A method for prognosis, risk assessment, risk stratification and/or diagnosis of a subject of developing late-onset Alzheimer's disease (LOAD), comprising:
- providing at least one sample isolated from said subject,
- determining in said at least one sample the presence of ApoE4 and at least one of:
- rs1799931(G), and/or
- rs8192506(A), rs7653308(C), rs968529(C) and rs9658265(A),
- wherein the presence or absence of ApoE4 and at least one of:
- rs1799931(G), and/or
- rs8192506(A), rs7653308(C), rs968529(C) and rs9658265(A)
- is indicative of a prognosis, a risk and/or a diagnosis of developing LOAD.
A method for the production of a pharmaceutical composition for use as a medicament in the treatment or prevention of LOAD in a subject at risk of developing LOAD, the method comprising:
- identifying an inhibitor of the enzymatic activity of NAT2, and
- mixing the identified compound or a derivative or homologue thereof with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.